Philip W. Peake

2.1k total citations
62 papers, 1.7k citations indexed

About

Philip W. Peake is a scholar working on Immunology, Nephrology and Molecular Biology. According to data from OpenAlex, Philip W. Peake has authored 62 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 17 papers in Nephrology and 15 papers in Molecular Biology. Recurrent topics in Philip W. Peake's work include Complement system in diseases (17 papers), Adipokines, Inflammation, and Metabolic Diseases (11 papers) and Acute Kidney Injury Research (8 papers). Philip W. Peake is often cited by papers focused on Complement system in diseases (17 papers), Adipokines, Inflammation, and Metabolic Diseases (11 papers) and Acute Kidney Injury Research (8 papers). Philip W. Peake collaborates with scholars based in Australia, Sri Lanka and New Zealand. Philip W. Peake's co-authors include J. A. Charlesworth, Yvonne Shen, Bruce A. Pussell, Lesley V. Campbell, Zoltán Endre, Nicholas A. Buckley, Warwick J. Britton, Timothy J. Pianta, John J. Kelly and Adamandia D. Kriketos and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Blood.

In The Last Decade

Philip W. Peake

62 papers receiving 1.7k citations

Peers

Countries citing papers authored by Philip W. Peake

Since Specialization

Citations

This map shows the geographic impact of Philip W. Peake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip W. Peake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip W. Peake more than expected).

Fields of papers citing papers by Philip W. Peake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip W. Peake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip W. Peake. The network helps show where Philip W. Peake may publish in the future.

Co-authorship network of co-authors of Philip W. Peake

This figure shows the co-authorship network connecting the top 25 collaborators of Philip W. Peake. A scholar is included among the top collaborators of Philip W. Peake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip W. Peake. Philip W. Peake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fab fragments of ovine antibody to colchicine enhance its clearance in the rat 2015 ·Clinical Toxicology ·Philip W. Peake, Timothy J. Pianta, Lena Succar, Mangalee Fernando, Nicholas A. Buckley, Zoltán Endre	12
2	Kidney damage biomarkers detect acute kidney injury but only functional markers predict mortality after paraquat ingestion 2015 ·Toxicology Letters ·Fahim Mohamed, Nicholas A. Buckley, Shaluka Jayamanne, John W. Pickering, Philip W. Peake, (unknown), (unknown), (unknown), Fathima Shihana, Zoltán Endre	43
3	A Comparison of the Ability of Levels of Urinary Biomarker Proteins and Exosomal mRNA to Predict Outcomes after Renal Transplantation 2014 ·PLoS ONE ·Philip W. Peake, Timothy J. Pianta, Lena Succar, Mangalee Fernando, (unknown), Kathleen McNamara, Zoltán Endre	39
4	Use of a glyphosate-based herbicide-induced nephrotoxicity model to investigate a panel of kidney injury biomarkers 2013 ·Toxicology Letters ·Klintean Wunnapuk, Glenda C. Gobé, Zoltán Endre, Philip W. Peake, Jeffrey E. Grice, Michael S. Roberts, Nicholas A. Buckley, Xin Liu	48
5	Review Article: Adiponectin: Its role in kidney disease 2008 ·Nephrology ·Yvonne Shen, Philip W. Peake, J. A. Charlesworth	24
6	Adiponectin binds C1q and activates the classical pathway of complement 2008 ·Biochemical and Biophysical Research Communications ·Philip W. Peake, Yvonne Shen, (unknown), J. A. Charlesworth	57
7	Glycosylation of human adiponectin affects its conformation and stability 2007 ·Journal of Molecular Endocrinology ·Philip W. Peake, Jaquelyne T. Hughes, Yvonne Shen, J. A. Charlesworth	31
8	Complement activation contributes to leukocyte recruitment and neuropathic pain following peripheral nerve injury in rats 2007 ·European Journal of Neuroscience ·Man Li, Philip W. Peake, J. A. Charlesworth, David J. Tracey, Gila Moalem‐Taylor	36
9	Human adiponectin binds to bacterial lipopolysaccharide 2006 ·Biochemical and Biophysical Research Communications ·Philip W. Peake, Yvonne Shen, Lesley V. Campbell, J. A. Charlesworth	49
10	Should we quantify insulin resistance in patients with renal disease? (Review Article) 2005 ·Nephrology ·Yvonne Shen, Philip W. Peake, John J. Kelly	22
11	Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes 2004 ·International Journal of Obesity ·Philip W. Peake, A. D. Kriketos, Lesley V. Campbell, J. A. Charlesworth	34
12	The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects 2003 ·International Journal of Obesity ·Philip W. Peake, A. D. Kriketos, Gareth Denyer, Lesley V. Campbell, J. A. Charlesworth	77
13	The effect of pH and nucleophiles on complement activation by human proximal tubular epithelial cells 2002 ·Nephrology Dialysis Transplantation ·Philip W. Peake	22
14	C3a is made by proximal tubular HK-2 cells and activates them via the C3a receptor 1999 ·Kidney International ·Philip W. Peake, (unknown), Bruce A. Pussell, J. A. Charlesworth	49
15	NITRIC OXIDE SYNTHASE INHIBITION IN A SPONTANEOUSLY HYPERTENSIVE RAT MODEL OF DIABETIC NEPHROPATHY 1997 ·Clinical and Experimental Pharmacology and Physiology ·(unknown), Philip W. Peake, (unknown), G. J. Macdonald	16
16	Detection and quantification of the control proteins of the alternative pathway of complement in 3T3‐L1 adipocytes 1997 ·European Journal of Clinical Investigation ·Philip W. Peake, (unknown), Bruce A. Pussell, J. A. Charlesworth	52
17	The inhibitory effect of rosmarinic acid on complement involves the C5 convertase 1991 ·International Journal of Immunopharmacology ·Philip W. Peake, Bruce A. Pussell, (unknown), (unknown), J. A. Charlesworth	74
18	Activation of Rabbit C3: Studies of the Generation of Cleavage Products in vitro and of Their Metabolism in vivo 1991 ·PubMed ·Philip W. Peake, J. A. Charlesworth, Bruce A. Pussell	8
19	The complement system in Type 1 (insulin-dependent) diabetes 1987 ·Diabetologia ·J. A. Charlesworth, (unknown), Jean Golding, Lesley V. Campbell, Philip W. Peake, Bruce A. Pussell, Denis Wakefield, (unknown)	28
20	Detection of lymphocytotoxic antibodies in relatives of patients with type I diabetes. 1986 ·BMJ ·J. A. Charlesworth, Philip W. Peake, (unknown), (unknown), Bruce A. Pussell, N. J. Howard, Grahame J. Elder	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact